Corrections:

Xinxing Li^1,*, Shifeng Teng^1,*, Yanyan Zhang^1,*, Weigang Zhang¹, Xianwen Zhang¹, Kai Xu¹, Houshan Yao¹, Jun Yao¹, Haolu Wang², Xiaowen Liang² and Zhiqian Hu¹

¹ Department of General Surgery, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China
² Therapeutics Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba QLD 4102, Australia
^* These authors have contributed equally to this work

Published: November 05, 2019

This article has been corrected: Due to errors in image processing, Figure 2C contains an image from the wrong cell line (GBC-SD cells). The corrected Figure 2C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:47052–47063. DOI: https://doi.org/10.18632/oncotarget.16789.

Figure 2: TROP2 expression in GBC cell lines. (A) The TROP2 protein expression of human GBC cell lines NOZ, GBC-SD, OCUG-1, SGC-996 and EH-GB-1B. (B) The TROP2 mRNA expression of human GBC cell lines NOZ, GBC-SD, OCUG-1, SGC-996 and EH-GB-1B. (C) TROP2 mRNA expressions of GBC-SD and SGC-996 cells after RNA interference and plasmid transfection. Cells were transfected with scramble sh-RNA and empty vector as negative controls. Each experiment was repeated three times.